Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merck buys Afferent for $500mm cash and $750mm in potential earn-outs

Executive Summary

Merck & Co. Inc. agreed to pay $500mm up front to acquire Afferent Pharmaceuticals Inc., a seven-year old private biotech developing treatments for neurogenic diseases.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Includes Earnout
    • Full Acquisition
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register